Health Canada Authorizes Rybrevant® (Amivantamab) in Combination With Carboplatin and Pemetrexed as the Only Targeted First-Line Treatment Approved for Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations
加拿大衛生部批准Rybrevant® (Amivantamab)與卡鉑和培美曲塞聯合使用，作爲EGFR外顯子20插入突變非小細胞肺癌唯一的靶向一線治療方案。